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SOX9 and SOX10 but Not BRN2 Are Required for
Nestin Expression in Human Melanoma Cells
Anna Flammiger1,3, Robert Besch1,3, Anthony L. Cook2, Tanja Maier1, Richard A. Sturm2 and Carola Berking1
Nestin is an intermediate filament protein and a marker of neuroectodermal stem cells indicating
multipotentiality and regenerative capability. In melanoma tissues, nestin re-expression was correlated with
tumor progression. Activation of the nestin neural enhancer was shown to be dependent on the binding of
class III POU transcription factors, with brain-2 (BRN2) suggested to play a key role. We found both nestin and
BRN2 mRNA in almost all of 13 analyzed melanoma cell lines of different progression stages, but expression
levels did not correlate. Nestin protein was detected in 11 of 13 and BRN2 protein in 7 of 13 melanoma cell lines
independent of progression stage. Downregulation of BRN2 by small-interfering RNA did not alter nestin
expression in melanoma cells. However, POU proteins, such as BRN2, commonly cooperate with transcription
factors of the Sry-box (SOX) family by binding to a nearby DNA site necessary for their action. SOX9 and SOX10
have been shown to be expressed in melanocyte precursors, with SOX10 downregulated upon differentiation.
We now demonstrate SOX9 and SOX10 protein expression in melanoma tissues and cell lines. Downregulation
of SOX9 and of SOX10 markedly decreased nestin levels in melanoma cells in a cooperative manner. Thus, SOX9
and SOX10 but not BRN2 seem to be required for nestin expression in human melanoma.
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INTRODUCTION
During development of the central nervous system (CNS),
cells express different classes of intermediate filaments in a
strict temporal and spatial order. In this manner, the
intermediate filament nestin is expressed by multipotent
neuroectodermal stem cells and regarded as a marker of
proliferating and migrating cells (Dahlstrand et al., 1992a, b).
Upon differentiation, nestin becomes downregulated and is
replaced by tissue-specific intermediate filament proteins.
However, upon regeneration of injured tissue of the CNS or
muscle nestin expression is re-induced (Moon et al., 2004;
Michalczyk and Ziman, 2005).
In cancer, tumor cells may show a pattern of gene
expression characteristic of the precursor cells of the original
tissue. Nestin re-expression has been demonstrated in a
variety of primary CNS tumors (Dahlstrand et al., 1992a, b;
Ehrmann et al., 2005) as well as in melanoma tissue
(Florenes et al., 1994; Brychtova et al., 2007). The potential
role of stem cells in cancer is a subject of recent interest
(for review see Huang et al., 2007), and current data
support the presence of stem cells in the pathogenesis of
melanoma (Fang et al., 2005; Grichnik et al., 2006;
Kamstrup et al., 2007). Expression of the stem cell markers
nestin, CD166 and CD133, in melanoma adds to this
hypothesis (Klein et al., 2007). Nestin expression during
embryonic stages of CNS development is largely regulated
by a nervous system-specific enhancer located in the
second intron (Josephson et al., 1998). Activation of the
nestin neural enhancer is dependent on the binding of class
III POU transcription factors, whereas other nuclear factors
such as the Sry-box (SOX) family (Wegner, 2005) may
cooperate in establishing this enhancer activity (Tanaka
et al., 2004). Among these SOX Group E transcription
factors SOX9 and SOX10 may be of special interest in
melanoma, because they have been shown to be coexpressed
in melanocytic cells (Cook et al., 2005; Passeron et al.,
2007).
POU domain factors are characterized by a highly
conserved DNA-binding domain referred to as the POU
domain (Andersen and Rosenfeld, 2001). The class III POU
domain subgroup consists of four closely related factors,
brain (BRN) 1, BRN2, BRN4, and OCT6. BRN2 seems to play
a key role in the activation of the nestin enhancer in
transfection assays. A 258-bp enhancer has been identified in
the mouse nestin gene that includes a binding sequence for
BRN2 (Tanaka et al., 2004). The human nestin gene also
contains an enhancer element that is 75% identical to the
mouse sequence in the corresponding 256-bp region, with a
binding site for BRN2 identical to the mouse sequence
(Tanaka et al., 2004).
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It was shown that BRN2 is expressed in human melanoma
cell lines and appears to play a role in melanoma cell
proliferation and tumorigenicity (reviewed by Cook et al.,
2006). Cook et al. (2003, 2005) investigated BRN2 and
SOX10 expression in human melanocyte precursors and
found both transcription factors to be inversely correlated
with the differentiation status of these cells. Other studies
showed that BRN2 is a focus for the convergence of MAP
kinase and Wnt/b-catenin signaling pathways that are linked
to cell proliferation (Goodall et al., 2004a, b).
Despite the demonstrated expression of BRN2, SOX10,
and nestin in human melanoma, it is not known if BRN2 or
SOX10 regulates nestin expression in this cancer cell type. To
establish a role for these transcription factors in melanocytic
nestin expression, we have investigated the differential
expression of nestin, BRN2, and SOX10 in melanoma. Our
results demonstrate that nestin, BRN2, and SOX10 are all
expressed in most primary and metastatic melanoma cell
lines. However, although BRN2 was not crucial for consti-
tutive nestin expression in melanoma, we demonstrate that
SOX10 and the related factor SOX9 are required for nestin
gene activation in human melanoma cells. Coexpression of
all these factors in human melanoma tissues was confirmed
by immunohistochemical analysis.
RESULTS
Expression of nestin and BRN2 mRNA
First, we analyzed the mRNA expression of nestin and BRN2
in 13 different melanoma cell lines by quantitative real-time
PCR (Figure 1a). Nestin mRNA was detected in 11 of 13
melanoma cell lines, whereas two metastatic lines showed no
expression (Figure 1a). Levels of nestin expression differed
considerably between the cell lines and did not correlate with
the stage of tumor progression defined as radial growth
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Figure 1. mRNA and protein expression of nestin and BRN2 in melanoma cell lines. (a) Expression levels of nestin and BRN2 mRNA were assessed by RT–PCR.
They are presented as mean of three independent experiments±standard deviation normalized relative to HPRT mRNA levels. Standard deviation of the cell line
WM278 was 444.95. (b) Protein expression of nestin and BRN2 in melanocytes, keratinocytes (Keratin.), fibroblasts (Fibrobl.), and melanoma cell lines was
assessed by western blot analysis. One representative of three independent experiments is shown. Detection of b-actin served as loading control. (c)
Cytoplasmatic localization of nestin protein is demonstrated by immunofluorescence in the metastatic cell line 1205Lu. Scale bar¼ 100mm (left panel) and
10mm (right panel).
946 Journal of Investigative Dermatology (2009), Volume 129
A Flammiger et al.
SOX9/10 and Nestin Expression in Melanoma
phase, vertical growth phase (VGP), or metastatic melanoma.
Nestin mRNA was also found in melanocytes and fibroblasts,
but not in keratinocytes (Figure 1a).
Brain-2 mRNA was detected in all melanoma cell lines
(Figure 1a). Levels of BRN2 expression were up to 103 times
higher in melanoma cell lines compared to normal melano-
cytes. BRN2 was restricted to the melanocytic lineage; no
expression was found in keratinocytes and fibroblasts. High-
est BRN2 mRNA levels were observed in VGP cell lines
WM278 and WM793 and in the metastatic cell line 1205Lu.
Comparing mRNA expression of nestin with BRN2 in
melanoma cell lines, no strict correlation was seen. In
selected cell lines, mRNA levels of nestin and BRN2 were
comparably low (SbCl2, WM3211, WM239A, WM9,
WM1232) or comparably high (WM1366, WM793,
1205Lu). Although in other cell lines, levels of nestin and
BRN2 differed considerably (WM3208, WM35, WM278).
Expression of nestin and BRN2 protein
Protein expression of nestin and BRN2 was assessed by
western blotting (Figure 1b). Results essentially corresponded
with mRNA expression with few exceptions. For example,
WM793 showed high amounts of BRN2 mRNA, but only a
weak band for BRN2 protein. Several cell line-specific
reasons may cause these differences including increased
proteolytic degradation in the proteasome, decreased transla-
tional activity, or increased RNA stability. High variability of
BRN2 mRNA levels in this cell line leading to a high-standard
deviation may further explain the limited correspondence
with protein expression.
Nestin protein was found in 11 of 13 melanoma cell lines
as well as in melanocytes and fibroblasts, but not in
keratinocytes. Immunofluorescence analysis of melanoma
cells demonstrated that nestin was localized to the cytoplasm
in an even distribution (Figure 1c).
Brain-2 protein was found in 7 of 13 melanoma cell lines,
but not in melanocytes, fibroblasts or keratinocytes (Figure
1b). The nuclear localization of BRN2 has been shown before
(Cook et al., 2003).
Strong protein expression of both nestin and BRN2 was
observed in metastatic cell lines 1205Lu and WM9 (Figure
1b). VGP cell line WM278 showed the highest expression of
BRN2 protein but was negative for nestin. Thus, similar to the
findings on mRNA level, there was no strict correlation
between protein expression of nestin and protein expression
of BRN2.
BRN2 is not essential for nestin expression in melanoma
To further investigate whether the expression of nestin in
melanoma is regulated by BRN2 as reported in the develop-
ing CNS, we specifically inhibited BRN2 by small-interfering
RNA (siRNA) in selected cell lines and analyzed nestin
thereafter. We chose metastatic melanoma cell lines 1205Lu
and WM9, because mRNA and protein expression of BRN2
and nestin, respectively, were abundantly found in these
lines. The downregulation of BRN2 protein was effective as
shown by western blotting 48 and 72 hours after transfection
with BRN2-specific siRNA of 1205Lu (Figure 2a) and WM9
(Figure 2b). Expression of nestin mRNA was analyzed 48 and
72 hours after transfection in 1205Lu (Figure 2c) and WM9
(Figure 2d) as well as 72 hours after re-transfection in 1205Lu
(Figure 2c). At all times nestin mRNA levels were not
significantly different between BRN2-ablated melanoma cells
and controls. The observed decrease in nestin mRNA levels
in all groups over time was probably due to the increased
confluency of cells during the time course of the experiments
leading to increased cell–cell contacts that implicate a
reduced cell motility connected with a decreased expression
of structural proteins such as nestin.
Likewise, analysis of nestin protein revealed no changes in
expression after BRN2 downregulation compared to the
controls (Figure 2e). This was also observed for metastatic
melanoma cell line A2058 (Figure 2f), which was originally
used to provide the BRN2 cDNA clone (Sturm et al., 1994;
Thomson et al., 1995). Neither reduction of nestin protein
was seen after inhibition of BRN2 nor reduction of BRN2
protein after inhibition of nestin. In summary, these results
indicate that downregulation of BRN2 is not sufficient to alter
nestin expression in melanoma cells.
SOX10 is required for nestin expression in melanoma
POU proteins, such as BRN2, commonly cooperate with
transcription factors of the Sry-box (SOX) family by binding to
a nearby DNA site for their action. Therefore, we investigated
SOX10 protein in melanoma, which was previously shown to
be highly expressed in unpigmented melanocyte precursors,
but not in differentiated melanocytes (Cook et al., 2005).
Immunoblot analysis for SOX10 protein levels in 11
melanoma cell lines demonstrated a correlation between
BRN2 and SOX10, such that cell lines with expression of
BRN2 also showed expression of SOX10, whereas cell lines
without detectable BRN2 protein also had no detectable
levels of SOX10 (Figure 3). This is consistent with previous
results observed using other melanoma cell lines, and with
the absence of SOX10 in BRN2-ablated human melanoma
cells (Cook et al., 2005).
As activation of the nestin enhancer described by Tanaka
et al. (2004) is also dependent on SOX10, we utilized siRNA
to downregulate SOX10 in melanoma cells. Although down-
regulation of BRN2 did not change nestin mRNA and protein
levels, silencing of SOX10 produced a decrease in nestin and
BRN2 mRNA levels, concomitant with a reduction in protein
levels as assessed by western blotting (Figure 4a and b). Thus,
it appears that unlike BRN2, SOX10 functions to regulate
nestin expression in melanoma cells.
SOX9 and SOX10 are required for nestin expression in
melanoma
The importance of SOX10 for the expression of nestin was
confirmed in other melanoma cell lines (Figure 5). As it has
been demonstrated before that SOX10 is coexpressed with
SOX9 in melanocytic cells (Cook et al., 2005), inhibition of
both SOX transcription factors alone and in combination
were tested. In metastatic melanoma cell line 1205Lu, nestin
mRNA and protein were downregulated by inhibition of
SOX10 as well as by inhibition of SOX9 (Figure 5a and b).
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Co-inhibition of both SOX9 and SOX10 by siRNA cotransfec-
tion of 1205Lu melanoma cells led to a synergistic reduction
in nestin levels (Figure 5a and b). Similarly, downregulation
of nestin by inhibition of SOX10 as well as of SOX9 was
observed in VGP melanoma cell line WM793, whereas co-
inhibition of SOX9 and SOX10 potentiated this effect (Figure
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Figure 2. BRN2 does not affect nestin expression in melanoma cells. Efficacy of BRN2-targeting siRNA was assessed by Western blot analysis in 1205Lu
(a) and WM9 (b) cell lines 2 and 3 days after transfection. The effect of BRN2 downregulation on nestin mRNA expression was investigated by quantitative
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transfection in A2058 melanoma cells (f). In (a–f) cells were either treated with BRN2-specific siRNA (BRN2), control siRNA (Neg Ctrl), transfection
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5c and d). Comparable results were obtained for metastatic
melanoma cell line WM239A (data not shown).
SOX9 and SOX10 are coexpressed in situ in primary melanomas
Immunohistochemical analysis of primary human melanoma
tissues demonstrated a strong expression of SOX9 (Figure 6c
and g) and, albeit with weaker intensity, of SOX10 (Figure 6b
and f). Coexpression was observed with nestin (Figure 6a
and e). BRN2 was only weakly detectable in the analyzed
tissues (Figure 6d and h).
DISCUSSION
Nestin expression has been studied in melanoma by
immunohistochemical staining of tissue sections (Florenes
et al., 1994; Ehrmann et al., 2005; Brychtova et al., 2007;
Klein et al., 2007). It was suggested that the expression of
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nestin is an indicator of cell de-differentiation, as nestin
protein was found to be more abundant in melanoma than in
benign nevi (Ehrmann et al., 2005; Brychtova et al., 2007).
However, Florenes et al. (1994) found that 75% of benign
nevi expressed detectable levels of nestin protein compared
to 67% of primary melanoma. We were interested in nestin
mRNA and protein expression in different human melanoma
cell lines and found no correlation with the stage of
melanoma progression. Relative levels of nestin mRNA
expression were not significantly different between radial
growth phase, VGP, or metastatic melanoma cell lines. Two
metastatic melanoma cell lines did not express any levels of
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Figure 6. Expression of nestin, SOX9, SOX10 and BRN2 in melanoma tissues in situ. Immunohistochemical analysis (red stain) of nestin (a, e), SOX10
(b, f), SOX9 (c, g), and BRN2 (d, h) expression in two different primary melanomas (arrows point to the tumor) of the skin (a–d and e–h). Nonspecific background
staining was seen in the epidermis of SOX9-stained sections (c). Scale bar¼ 100 mm.
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nestin mRNA, whereas four others did (66% positive). This is
consistent with previous studies given that nestin expression
was found in around 70% of metastatic melanoma tissue
samples (Florenes et al., 1994; Klein et al., 2007). However,
Brychtova et al. (2007) found nestin protein expression more
abundant in nodular melanoma than in melanoma metas-
tasis. Interestingly, our results suggest that nestin is also
expressed in normal melanocytes and fibroblasts in culture.
This implicates that nestin expression is not restricted to cells
of neuroectodermal origin, but also appears in cells that are
derived from the mesoderm. Similar findings were obtained
by Steinert et al. (1999), who described nestin expression in
fibroblastic cells such as NIH3T3 and primary human
foreskin fibroblasts, but not in primary human epidermal
foreskin keratinocytes. Cytoplasmatic localization of nestin
(Figure 1c) confirmed its role as a structural component of the
cell. It has been reported that nestin regulates the assembly
and disassembly of intermediate filaments that together with
other structural proteins, participate in remodeling of the cell
(Michalczyk and Ziman, 2005).
BRN2 mRNA was expressed in all melanoma cell lines.
Normal melanocytes showed only weak BRN2 mRNA
expression when compared with melanoma cells and no
BRN2 protein was detected by western blotting though this
has previously been detectable by the more sensitive
electrophoretic mobility shift assay DNA-binding assay (Cook
et al., 2003). Highest BRN2 expression was observed in the
vertical growth phase melanoma cell lines WM278 and
WM793 and in the metastatic melanoma cell line 1205Lu. A
good explanation for this finding is that these three cell lines
are characterized by BRAF V600E mutations (Smalley et al.,
2006), which have been shown to enhance BRN2 expression
(Goodall et al., 2004b).
Eisen et al. (1995) showed that BRN2 activates the MHC
class II DRa promoter, which is frequently upregulated in
melanoma but represses the activity of the melanocyte-
specific tyrosinase promoter, yet other target genes for the
regulation by BRN2 remain to be identified. One attractive
target for regulation by BRN2 is nestin (Tanaka et al., 2004),
thus we investigated the relation of BRN2 and nestin in
melanoma. There was no effect on nestin expression in three
different melanoma cell lines tested. However, as we were
only using transient assays it is possible that in permanently
transfected cells different results would have become
apparent. Indeed, cell-cycle-specific regulation of nestin
through phosphorylation of BRN2, which inhibits its DNA-
binding activity, has only recently been suggested to occur in
cortical neural progenitor cells of transgenic mice in which
the second intronic enhancer region of the nestin gene was
used to direct expression of a fluorescent marker protein
(Sunabori et al., 2008).
Another possible explanation would be that there are other
transcription factors that contribute to nestin activation in
melanoma. It is common for POU proteins such as BRN2 to
cooperate with SOX proteins by binding to a nearby DNA site
for their action (Dailey and Basilico, 2001). Interaction of
BRN2 with SOX10, which is important for correct melano-
cytic development, has been identified and it was shown that
BRN2-ablated melanoma cells also lack expression of SOX10
(Smit et al., 2000; Cook et al., 2005). Here we show that,
unlike BRN2, SOX10 does have an effect on nestin
expression in melanoma. Recently, SOX9 another member
of the SOX transcription factor family has been identified in
melanoma and it was demonstrated that siRNA downregula-
tion of BRN2 caused an increase of SOX9 expression in
melanoma cells indicating that expression of these factors is
inversely related (Cook et al., 2005). SOX9 has also been
implicated in melanocyte differentiation and pigmentation in
response to UVB exposure of the skin (Passeron et al., 2007).
As discussed previously (Cook et al., 2005, 2006), it is not
uncommon for specific POU and SOX protein family
members to be coexpressed in a given tissue in a coordinated
manner, where they exert their transcriptional regulatory
activities. In this study, we show for the first time that SOX9
and SOX10 are expressed in melanoma tissues and that both
factors are involved in the activation of nestin expression in
melanoma cell lines. The additive effects of SOX9 and
SOX10 loss on nestin expression levels is indicative of
functional redundancy of these factors, as has recently been
reported in the oligodendocyte lineage differentiation path-
way (Finzsch et al., 2008).
In conclusion, we show that the intermediate filament
protein and stem cell marker nestin as well as the lineage
restricted transcription factors BRN2, SOX9, and SOX10 are
expressed in melanoma cell lines of all progression stages as
well as in melanoma tissues. Our results from transiently
siRNA-mediated downregulation of BRN2, SOX9, and
SOX10 indicate that SOX9 and SOX10 but not BRN2 can
alter nestin expression in melanoma.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines were a gift of M. Herlyn (Wistar
Institute, Philadelphia, PA). They were isolated from primary
melanoma or melanoma metastasis and are classified according to
the histopathological stage in radial growth phase melanoma, VGP
melanoma, and melanoma metastasis (Herlyn et al., 1985). Radial
growth phase melanoma cell lines included SbCl-2, WM3211,
WM3208, and WM35. VGP cell lines included WM1366, WM793,
and WM278. Metastatic cell lines were derived from lymph nodes
(WM1158, WM239A, WM9) or lung (1205Lu, 451Lu). A2058 is a
human metastatic melanoma cell line derived from lymph node from
the American Type Culture Collection (Manassas, VA) (Sturm et al.,
1994). Melanoma cells were cultured as described previously (Besch
et al., 2007).
Primary melanocytes, keratinocytes, and fibroblasts were isolated
from human foreskins and cultured as described before (Berking
et al., 2001).
Culture conditions were 37 1C and 5% CO2 and cells were
replenished with fresh medium twice a week.
RNA extraction and quantification
RNA was extracted and reverse transcribed as described previously
(Besch et al., 2007). Quantitative reverse transcriptase-PCR (RT-PCR)
was performed using Fast Start DNA Master plus SYBR Green I
(Roche Diagnostics, Mannheim, Germany) for the analysis of BRN2
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and nestin expression. Primers were synthesized by MWG Biotech
(Ebersberg, Germany).
Reverse transcriptase-PCR with Fast Start DNA Master plus SYBR
Green I was carried out with 100 ng cDNA and 10 pmol of each
primer in a final volume of 20 ml. The primer sequences for SYBR
Green RT-PCR were 50-GCAAAAGGAAAGCAACTAAGAC-30 (for-
ward) and 50-CCATCTCTCTGTCTCTCTCTC-30 (reverse) for BRN2,
50-CTCCAGAAACTCAAGCACC-30 (forward) and 50-TGATTCCTGA
TTCTCCTCTTCC-30 (reverse) for nestin, and 50-GACTTTGCTTTCC
TTGGTCA-30 (forward) and 50-GGCTTTGTATTTTGCTTTTCC-30
(reverse) for hypoxanthine-phosphoribosyl-transferase (HPRT). Am-
plification conditions were 95 1C for 15 seconds, 55 1C for 10 sec-
onds, and 72 1C for 15 seconds for BRN2 and nestin, and 95 1C for
10 seconds, 50 1C for 15 seconds, and 72 1C for 25 seconds for HPRT.
Specific amplification was controlled by melting curve analysis.
Quantitative PCR for SOX9 and SOX10 was performed using the
LightCycler TaqMan Master Kit (Roche) together with the Universal
ProbeLibrary system (Roche).
Relative gene expression was normalized to the expression of the
housekeeping gene HPRT. mRNA expression of nestin, BRN2,
SOX9, and SOX10 in melanoma cell lines is presented as mean of
three independent experiments±standard deviation.
Protein extraction and Western blot analysis
Protein extraction and Western blot analysis were carried out as
described before (Besch et al., 2007). Primary antibodies for Western
blot analysis were directed against Brn-2 (goat polyclonal, C-20;
Santa Cruz Biotechnology Inc., Santa Cruz, CA; 1:200), nestin
(mouse monoclonal, 10c2; Santa Cruz Biotechnology Inc.; 1:200),
SOX9 (rabbit polyclonal, no. AB5535; Chemicon, Temecula, CA),
SOX10 (goat polyclonal, N-20) (Santa Cruz Biotechnology Inc.), and
b-actin (Sigma, Taufkirchen, Germany; 1:4000). Secondary horse-
radish peroxidase-linked antibodies were purchased from Santa Cruz
Biotechnology Inc. and Cell Signaling Technology (Danvers, MA).
Immunofluorescence cell staining
Melanoma cells were grown on four-well culture slides (BD
Biosciences, Bedford, MA) to a confluence of about 90%. Cells
were fixed in 4% paraformaldehyde and permeabilized with 0.5%
Triton X-100 (Sigma). After blocking with 20% fetal bovine serum,
cells were incubated with the primary antibody (1:500) overnight at
4 1C. After washing with phosphate-buffered saline incubation with
the secondary antibody (1:200), followed for 1 hour in a dark room.
Analysis of stained cells was performed with a Zeiss Axiovert 25
microscope connected to a Sony 3CCD color video camera.
Negative controls were incubated with phosphate-buffered saline
only instead of the primary antibody.
Primary antibody was nestin (10c2) antibody from Santa Cruz
Biotechnology Inc. and secondary antibody was a Cy3-conjugated
anti-IgG1 antibody (Jackson Immunoresearch Laboratories Inc., West
Grove, PA).
Immunohistochemistry
Paraffin-embedded sections (5 mm) of primary human melanomas
were deparaffinized in xylene and rehydrated in a graded series of
isopropanol. Antigen retrieval was achieved by microwave in citrate
buffer, pH 6.0 (Chemicon). Blocking of unspecific binding was
performed with fetal calf serum/Tris 20%. Primary antibodies used
were a polyclonal rabbit anti-human BRN2 (Smith et al., 1998),
rabbit anti-human SOX9 (ab36748, Abcam, Cambridge, UK), rabbit
anti-human SOX10 (ab25978, Abcam), and a monoclonal mouse
anti-human NES IgG1 (sc-23927, Santa Cruz Biotechnology Inc.).
Secondary antibodies were mouse anti-rabbit antibody (M0737,
Dako, Glostrup, Denmark) and alkaline phosphatase-conjugated
rabbit anti-mouse antibody (Z0259 DAKO). Immunostaining was
performed using the alkaline phosphatase anti-alkaline phosphatase
method (D0651, Dako). Fast Red (Sigma-Aldrich, Steinheim,
Germany) was used as substrate and Mayer’s hematoxylin as
counterstaining. The sections were mounted in Kaiser’s glycerol
gelatine.
Transfection with siRNAs
Small-interfering RNAs were obtained from MWG Biotech (Ebers-
berg, Germany). The siRNA oligonucleotide targeting the BRN2
transcription factor has been described by Goodall et al. (2004b) (50-
GCGCAGAGCCUGGUGCAGG-30 and its complement). The
sequence of SOX9 siRNA was 50-CAGCGAACGCACATCAAGA-30,
of SOX10 siRNA was 50-CCGTATGCAGCACAAGAAA-30, and of
nestin siRNA was 50-AGACATCATTGGTGTTAAT-30 and its comple-
ment, respectively. CO3 and CO4 were used as control nonsilencing
siRNAs. The sequence of CO3 was 5
0-GCGCATTCCAGCTTACGT
A-30 and of CO4 was 50-GCGCUAUCCAGCUUACGUA-30 and its
complement. 1.5 ml siRNA (20mM) diluted in 125 ml Opti-MEM
(Invitrogen, Karlsruhe, Germany) and 1.25ml Lipofectamine RNAi-
Max (Invitrogen) diluted in 125ml Opti-MEM were mixed and
incubated for 20minutes at room temperature for complex forma-
tion. This mixture was added to melanoma cells in 3.5 cm dishes at
about 70% confluence together with culture medium to a final
volume of 1.5ml. Cells were re-transfected 3 days after the first
transfection by adding new transfection mixture in 1.5ml culture
medium.
siRNA transfection of A2058 melanoma cells
Growth, transfection, and analysis of protein and mRNA levels of
A2058 melanoma cells were as previously described (Cook et al.,
2005). Briefly, we used a commercially available negative control
siRNA for comparison to siRNA molecules targeting BRN2, SOX10,
or nestin (ID 135939). Isolation and analysis of mRNA levels was
performed, using predesigned TaqMan assays for gene expression
levels of BRN2, SOX10, and b-2-microglobulin were as described.
Nestin mRNA levels were determined using Assay ID
Hs00707120_s1 (Applied Biosystems, Foster City, CA). Normal-
ization to b-2-microglobulin was performed and for each gene is
presented relative to appropriate negative control mRNA levels.
Western immunoblotting of total protein lysates was performed using
antibodies to BRN2, SOX10, and IFA as described, or with
antibodies specific for human nestin (1:1000 dilution in 5% skim-
milk powder overnight a 4 1C; MAB5326 Chemicon).
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